Compare PKOH & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKOH | CHRS |
|---|---|---|
| Founded | 1907 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.5M | 296.8M |
| IPO Year | 1994 | 2014 |
| Metric | PKOH | CHRS |
|---|---|---|
| Price | $29.78 | $1.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $37.00 | $5.51 |
| AVG Volume (30 Days) | 46.8K | ★ 927.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ 1.70 | 1.43 |
| Revenue | ★ $1,599,100,000.00 | N/A |
| Revenue This Year | $7.87 | $73.08 |
| Revenue Next Year | $3.42 | $30.94 |
| P/E Ratio | $17.07 | ★ $1.21 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.52 | $0.72 |
| 52 Week High | $30.45 | $2.62 |
| Indicator | PKOH | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 51.44 |
| Support Level | $19.21 | $1.55 |
| Resistance Level | N/A | $1.89 |
| Average True Range (ATR) | 1.51 | 0.10 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 80.86 | 31.82 |
Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.